Supernus Pharma (SUPN) Misses Q4 EPS by 25c

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.43, $0.25 worse than the analyst estimate of $0.68. Revenue for the quarter came in at $167.33 million versus the consensus estimate of $180.38 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
• ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs